Share on StockTwits

Applied Genetic Technologies Corp (NASDAQ:AGTC) shares reached a new 52-week high during trading on Friday , Analyst Ratings Net reports. The company traded as high as $29.63 and last traded at $27.37, with a volume of 37,864 shares trading hands. The stock had previously closed at $25.87.

Several analysts have recently commented on the stock. Analysts at BMO Capital Markets raised their price target on shares of Applied Genetic Technologies Corp from $21.00 to $34.00 in a research note on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks initiated coverage on shares of Applied Genetic Technologies Corp in a research note on Wednesday, April 30th. They set a “hold” rating on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Applied Genetic Technologies Corp in a research note on Monday, April 21st. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $27.50.

The stock’s 50-day moving average is $15.21 and its 200-day moving average is $14.93. The company’s market cap is $385.9 million.

Applied Genetic Technologies Corp (NASDAQ:AGTC) last released its earnings data on Wednesday, May 14th. The company reported ($25.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $25.08. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.15 million. Analysts expect that Applied Genetic Technologies Corp will post $-14.11 EPS for the current fiscal year.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.